Gambro breaks into Turkey through clinic purchase:
This article was originally published in Clinica
Swedish company Gambro has bought the Bulten dialysis centre, as well as a local sales company, in Turkey - its first move into this market, where it immediately takes a 10-12% share of the market for dialysis products. "The acquisition is a clear signal that we intend to move into this strategically important market, a market with more patients than Spain and almost as big as France," said Lennart la Fleur, managing director of Gambro Export. Over the past few years, the Turkish dialysis market has been growing at 15% annually.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.